Trial reportHeart rhythm2025
Accelerated Bachmann bundle area pacing for atrial resynchronization in patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction: A randomized crossover trial.
Trial report in Heart rhythm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- AI-Enabled ECG Mapping to Guide Leadless Atrial Pacemaker Implantation in the Bachmann's Bundle Region.JACC. Case reports · 2026Article
- Atrial electrogram amplitude-guided Bachmann bundle pacing implantation: A single-center experience.Heart rhythm O2 · 2026Article
- Transcatheter epicardial pacing of the human Bachmann's bundle via the transverse sinus: Novel technique to expand transcatheter cardiac intervention.HeartRhythm case reports · 2026Article
- Cardiac implantable electronic devices in heart failure: needs, challenges, and real-world implementation.Heart failure reviews · 2026Review
- Leadless Atrial Pacing at Bachmann's Bundle Guided by Electroanatomic Mapping and Intracardiac Ultrasound.Journal of cardiovascular electrophysiology · 2026Article
- Electrophysiological characterization of the Bachmann bundle region using 3D electroanatomical mapping and peak frequency analysis during pacemaker lead implantation.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Bachmann's bundle pacing: toward physiologic atrial activation.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
- AssociatedDataset
- AssociatedDataset
- AssociatedDataset
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInter-atrial block (IAB) can contribute to the worsening of diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF).
objectiveTo determine the effects of accelerated Bachmann bundle area pacing (BBAP) in symptomatic patients with non-obstructive hypertrophic cardiomyopathy (nHCM), HFpEF, and IAB.
methodsProspective, randomized, patient-blinded crossover study in symptomatic patients with nHCM, HFpEF, and IAB. Patients were recruited during 2021-2024 for dual-chamber implantable cardioverter defibrillator (ICD) implantation. Patients with successful BBAP were randomized to dual-chamber rate-responsive pacing (DDDR 70/min) or no pacing (VVI 30/min) for 4 weeks. After a washout period of 4 weeks, they were crossed over to the other arm for 4 additional weeks. In addition, a historical cohort of nHCM patients with an atrial lead in the right atrial appendage pacing (RAAP) were programmed to DDDR 70/min for 12 weeks. The primary end point was a change in N-terminal pro-brain natriuretic peptide (NT-proBNP). Secondary end points included 6-minute walk distance, functional class, diastolic filling parameters, and daily diuretic requirement.
resultsOf 46 patients recruited, 42 patients had successful BBAP and were randomized (age 46.2 ± 7.2 years, 82.6% men). BBAP significantly reduced the N-terminal pro-brain natriuretic peptide (NT-proBNP), compared with no pacing (-116.4 ± 22.1 vs -8.1 ± 6.2, P = .008) and RAAP (-116.4 ± 22.1 vs -27.1 ± 12.6, P = .021). BBAP also led to an improvement in all the secondary end points. Compared with the historical cohort of RAAP, BBAP was associated with a significant reduction in NT-proBNP levels (-116.4 ± 22.1 vs -27.1 ± 12.6, P = .021) and all secondary end points.
conclusionAmong patients with nHCM, HFpEF, and an IAB, accelerated BBAP was found to reduce the NT-proBNP and was accompanied by an improvement in the diastolic function and exercise capacity.
Indexed as
Identifiers
40714334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.